University of Kansas Medical Center

Conditions

• Lung Non-Small Cell Carcinoma
• Lung Non-Small Cell Squamous Carcinoma
• Lung Non-Squamous Non-Small Cell Carcinoma
• Stage II Lung Cancer AJCC v8
• Stage IIIA Lung Cancer AJCC v8
• Stage IIIB Lung Cancer AJCC v8

Eligibility

Eligible Ages

Over 18 Years

Eligible Genders

All

Accepts Healthy Volunteers

No

Criteria

Inclusion Criteria:

- A female of childbearing potential is a sexually mature female who:

- Has not undergone a hysterectomy or bilateral oophorectomy; or

- Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
has had menses at any time in the preceding 12 consecutive months)

- Previously registered to A151216

- Central and/or local testing of EGFR with no EGFR exon 19 deletion or EGFR L858 R
mutation (applicable to non-squamous patients only)

- Central and/or local testing of ALK with no ALK rearrangement (failed testing is
considered negative) (applicable to non-squamous patients only)

- Central and/or local testing of PD-L1 immunohistochemistry (IHC) using one of the
following assays: DAKO 22C3, DAKO 28-8, EIL3N or SP263

- Note: Central testing of EGFR was discontinued as of A081801 Update 10; central
testing of ALK and PD-L1 will continue. Local testing results by a local CLIA
certified laboratory is required for EGFR and acceptable for ALK. The report
must indicate the result as well as the CLIA number of the laboratory that
performed the assay. Local result of PD-L1 by DAKO 22C3, Dako 28-8, EIL3N or
SP263 are acceptable for enrollment on A081801. Patients with local results for
EGFR, ALK and PD-L1 still need to be registered to A151216 and follow all the
submissions requirements but do NOT need to wait for the results to proceed to
A081801 registration.

- Completely resected stage IIA, IIB IIIA or IIIB (T3-4N2) non-small cell lung cancer
(NSCLC) (squamous or non-squamous) with negative margins (complete R0 resection).
Patients will be staged according to the 8th edition of the American Joint Committee
on Cancer (AJCC) Staging Manual, 2017

- Note: Patients with pathologic N2 disease, completely resected, are eligible.
However, patients known to have N2 disease prior to surgery are not eligible;
guidelines do not recommend up-front surgery for this population

- Complete recovery from surgery. Registration to A081801 must be 30-77 days following
surgery

- No prior neoadjuvant or adjuvant therapy for current lung cancer diagnosis

- No prior allogeneic tissue/solid organ transplant

- Patients must NOT have uncontrolled intercurrent illness including, but not limited
to, serious ongoing or active infection, symptomatic congestive heart failure,
uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit
compliance with study requirements

- No current pneumonitis or history of (non-infectious) pneumonitis that required
steroids

- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial

- Age >= 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-1

- No active auto-immune disease that has required systemic treatment within the last 2
years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive drugs).
Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release
therapy for adrenal or pituitary insufficiency) is not considered a form of systemic
treatment

- Not pregnant and not nursing, because this study involves an agent that has known
genotoxic, mutagenic and teratogenic effects

- Therefore, for women of childbearing potential only, a negative pregnancy test
done =< 7 days prior to registration is required

- No patients with a "currently active" second malignancy that is progressing or has
required active treatment within the last 3 years. Participants with non-melanoma
skin cancers or carcinoma in situ (e.g., breast carcinoma or cervical cancer in
situ) that have undergone potentially curative therapy are eligible

- No hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients

- No live vaccine within 30 days prior to registration. Examples of live vaccines
include, but are not limited to, the following: measles, mumps, rubella,
varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin
(BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally
killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,
FluMist) are live attenuated vaccines and are not allowed

- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]
reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA]
[qualitative] is detected) infection

- Absolute neutrophil count (ANC) >= 1,500/mm^3

- Platelet count >= 100,000/mm^3

- Hemoglobin >= 8 gm/dl

- Calculated (Calc.) creatinine clearance >= 45 mL/min

- Total bilirubin =< 1.5 x upper limit of normal (ULN)

- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper
limit of normal (ULN)

Recruiting Locations

Study Contact

Detailed Description

PRIMARY OBJECTIVE: I. To compare the disease free survival (DFS) between Arm B versus (vs) Arm C in patients with stage IIA-IIIB (T3-4N2) non-small cell lung cancer. SECONDARY OBJECTIVES: I. To compare the overall survival (OS) between the two treatment arms in patients with stage IIA-IIIB (T3-4N2) non-small cell lung cancer. II. To compare the adverse event rates and drug discontinuation rates due to adverse events in patients with stage IIA-IIIB (T3-4N2) non-small cell lung cancer. III. To compare the adverse event (AE) rates for Arms B and C with A (prior to Update #7) and estimate the DFS and OS in Arm A. IV. To compare the DFS and OS in patients with stage IIA-IIIB (T3-4N2) non-small cell lung cancer that receive at least 2 cycles of initial adjuvant chemotherapy. QUALITY OF LIFE OBJECTIVES: I. To compare patient-reported quality of life (QOL) one year after randomization as assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core (C)30 between patients randomized to receive adjuvant chemotherapy followed by pembrolizumab (Arm B), and those randomized to receive adjuvant chemotherapy + pembrolizumab concomitantly (Arm C). II. To compare patient-reported QOL at completion of chemotherapy as assessed by the EORTC QLQ-C30 between patients randomized to receive adjuvant chemotherapy followed by pembrolizumab (Arm B) and those randomized to receive adjuvant chemotherapy + pembrolizumab concomitantly (Arm C). III. To present longitudinal trajectories by arm of patient-reported dyspnea and coughing as assessed by the EORTC QLQ-Lung Cancer (LC13). CORRELATIVE SCIENCE OBJECTIVES: I. To compare the DFS and OS in the PD-L1 subgroup of patients with PD-L1 expression status (>= 1% vs < 1%). II. To compare the DFS and OS by tumor mutational burden status (high vs. low) in patients with stage IIA-IIIB (T3-4N2) non-small cell lung cancer. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A (CLOSED AS OF UPDATE #7 on 2/1/2022): INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then undergo observation. ARM B: INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab intravenously (IV) over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 17 cycles or every 6 weeks for 16 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity. ARM C: INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiogram (ECHO) as clinically indicated during screening and on the trial. Patients may undergo magnetic resonance imaging (MRI) during screening and as clinically indicated on the trial, as well as computed tomography (CT) and blood sample collection throughout the trial. *ACCEPTABLE REGIMENS: DOUBLET I: Patients receive cisplatin IV and pemetrexed IV over 10 minutes on day 1 of each cycle. DOUBLET II: Patients receive carboplatin IV over and pemetrexed IV over 10 minutes on day 1 of each cycle. DOUBLET III: Patients receive cisplatin IV on day 1 of each cycle and gemcitabine hydrochloride IV on days 1 and 8 of each cycle. DOUBLET IV: Patients receive carboplatin IV and paclitaxel IV over 1-96 hours on day 1 of each cycle. After completion of study treatment, patients are followed up at 6 weeks, then every 3 months for 2 years from randomization, every 6 months for years 2-4 from randomization, and then annually for up to 10 years from randomization.